Journal of Leukocyte Biology eBioscience full spectrum cell analysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Werr, J.
Right arrow Articles by Lindbom, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Werr, J.
Right arrow Articles by Lindbom, L.
(Journal of Leukocyte Biology. 2000;68:553-560.)
© 2000 by Society for Leukocyte Biology

Engagement of ß2 integrins induces surface expression of ß1 integrin receptors in human neutrophils

Joachim Werr, Einar E. Eriksson, Per Hedqvist and Lennart Lindbom

Department of Physiology and Pharmacology, Karolinska Institutet, S-171 77 Stockholm, Sweden

Correspondence: Joachim Werr, Department of Physiology and Pharmacology, Karolinska Institutet, S-171 77 Stockholm, Sweden. E-mail: joachim.werr{at}fyfa.ki.se


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Induction of ß1 integrin (CD49/CD29) expression in polymorphonuclear leukocytes (PMN) has been shown to be associated with transendothelial migration recently. Yet, ß1 integrin expression is relatively insensitive to cell activation with soluble agonists, such as N-formyl-methionyl-leucyl-phenylalanine (fMLP). We hypothesized that ß2 integrins (CD11/CD18), critically involved in PMN adhesion and extravasation, may play a role in regulating ß1 integrin expression in PMN. Antibody cross-linking of CD18, mimicking adhesion-dependent engagement of ß2 integrins, resulted in rapid, tyrosine kinase-dependent upregulation of ß1 integrins. This response was potentiated by simultaneous chemoattractant (fMLP) stimulation of PMN. Moreover, upregulation of ß1 integrins evoked by CD18 cross-linking was found to support adhesion of fMLP-stimulated PMN to matrix proteins and also was critical for the ability of PMN to migrate in collagen gels in response to a gradient of fMLP. Taken together, these data demonstrate that engagement of ß2 integrins in human PMN induces ß1 integrin expression in these cells of significance for their migration in the extravascular tissue. Thus, ß2 integrins may serve the function to regulate PMN locomotion in extravascular tissue via receptor crosstalk with ß1 integrins.

Key Words: inflammation • leukocytes • adhesion • extravasation • migration


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The recruitment of polymorphonuclear leukocytes (PMN) to sites of infection or tissue injury is regulated by the function of cell adhesion molecules [1 ]. Initial steps in the PMN extravasation process are mediated predominantly by cell adhesion molecules of the selectin and ß2 integrin families [2 ]. Conversely, subsequent PMN interactions with matrix components of extravascular tissue are likely to be regulated by receptors that specifically bind to matrix proteins, such as fibronectin, collagen, laminin, and vitronectin [3 4 5 6 ]. Among such receptors are the ß1 integrins (CD49/CD29), a family consisting of a series of heterodimeric receptors, each containing a common ß1 subunit that is associated with one of several (at least 10) different {alpha} subunits [2 , 7 , 8 ]. Several studies have shown that all leukocyte subsets, with the exception of PMN, constitutively express ß1 integrins that mediate cell binding to different extracellular matrix components, including collagens, fibronectin, and laminin [7 , 9 ]. However, limited expression of ß1 integrins has been identified on circulating PMN also [4 , 10 11 12 ], and accumulating data indicate that ß1 integrins can be rapidly upregulated on PMN under certain circumstances in the inflammatory process [3 , 6 , 13 , 14 ]. Thus, although expression of ß1 integrins in circulating PMN is relatively insensitive to chemoattractant stimulation [10 ], increased expression may be induced in conjunction with transendothelial migration [3 , 6 , 13 ]. We recently demonstrated that ß1 integrins are upregulated in extravasated human PMN and that PMN migration in extravascular tissue is largely dependent on the function of {alpha}2ß1 integrin [15 ]. Together, these findings indicate that expression of ß1 integrins, although sparse on circulating PMN, is induced in association with the extravasation of these cells and that members of the ß1 integrin family play an important role in PMN recruitment to extravascular tissue.

ß2 Integrins (CD11/CD18) are of fundamental importance for PMN firm attachment to the endothelium in inflamed tissue, and they have been shown to play critical roles in several steps of PMN activation also [2 ]. There is a growing body of evidence that activation of one family of adhesion molecules may regulate the activity of another and that ß2 integrins are involved in such mechanisms of receptor crosstalk [16 17 18 ]. In light of these findings and the fundamental role that has been attributed to ß2 integrins in PMN activation, this study was aimed at exploring the possibility that signaling by ß2 integrins, consequent to ligand binding, may be involved in emigration-associated upregulation of ß1 integrins on PMN. Through antibody cross-linking of CD18, it was revealed that ß2 integrin engagement triggers induction of ß1 integrin surface expression in PMN. Furthermore, this mode of activation was shown to induce ß1 integrin-dependent PMN adhesion to matrix proteins and to stimulate PMN motility in collagen gels.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Antibodies
The following monoclonal antibodies (mAbs) with documented function blocking activity in human systems were used: P1E6 and 12 F1 (Pharmingen, San Diego, CA) recognizing the {alpha}2 (CD49b) integrin subunit, L25.3 (Pharmingen) reacting with the {alpha}4 (CD49d) subunit, mAb16 (Pharmingen) reacting with the {alpha}5 (CD49e) subunit, mAb13 (Pharmingen) against the common ß1 (CD29) integrin chain, and IB4 (courtesy of Dr. Samuel Wright, The Rockefeller University, New York) against the common ß2 (CD18) integrin chain. All antibodies employed were mouse immunoglobulin G (IgG), except mAb13, a rat IgG.

Isolation of human PMN
Human PMN were isolated from whole blood by single-step density centrifugation over Polymorphprep (Nycomed Pharma AS, Oslo, Norway). Briefly, blood (5 ml) was layered onto 3 ml of the separation medium and centrifuged at room temperature at 500 g for 30 min. The PMN-rich band was collected and washed twice in ice-cold Hanks’ balanced saline solution (HBSS). Contaminating erythrocytes were lysed by 20 sec hypotonic shock, and PMN were washed and resuspended in culture medium [modified Eagle’s medium (MEM); Life Technologies, Gaithersburg, MD] again at concentrations indicated.

PMN activation and CD18 cross-linking
Isolated PMN (1x106 cells/ml) were incubated with 10 µg/ml of anti-CD18 mAb IB4 at 4°C for 40 min, washed twice at 150 g for 7 min, and resuspended in ice-cold MEM. Cross-linking of surface-bound IB4 was then induced by incubating the cells with goat anti-mouse F(ab')2 fragments (Jackson ImmunoResearch Laboratories, West Grove, PA; final dilution, 1:20) at conditions indicated below for the different experimental procedures. In those cases where N-formyl-methionyl-leucyl-phenylalanine (fMLP; Sigma, St. Louis, MO) was used to activate PMN, either in combination with CD18 cross-linking or alone, the chemoattractant was present throughout all steps of incubation at a final concentration of 10-6 M. Herbimycin A (Sigma) was used as a tyrosine kinase inhibitor at a final concentration of 30 µM. PMN were pretreated with herbimycin A for 10 min at 37°C before exposure to antibodies and/or fMLP, and the substance was present at the same concentration during all the following incubation steps.

Immunofluorescence flow cytometric analysis
Incubation of PMN with anti-CD18 mAb (IB4), with or without fMLP (10-6 M), was performed according to the protocol above. Ligation of CD18 was induced by incubation with goat anti-mouse F(ab')2, first at 4°C for 20 min and then at 37°C for specified time periods (5, 20, and 30 min). PMN were then fixed in 4% paraformaldehyde (Sigma) at room temperature for 20 min, washed twice, and resuspended in HBSS at 4°C to yield a final concentration of 20 x 106 cells/ml. The fixed PMN were incubated with saturating concentration of mouse IgG (Pharmingen; final dilution, 1:20) at room temperature for 30 min to prevent binding of integrin antibodies to cell surface-bound F(ab')2 fragments. PMN were then incubated with fluorescein isothiocyanate (FITC)-conjugated anti-ß1 integrin mAb (mAb13), rat IgG (10 µg/ml), or FITC-conjugated, isotype-matched control antibody for 20 min at 4°C in the dark. A rat IgG (mAb13) was chosen for detection of ß1 integrin in an effort to minimize binding to the cell surface-bound, goat anti-mouse F(ab')2 fragments. PMN were washed twice and analyzed on a FACSort flow cytometer (Becton Dickinson, Mountain View, CA). Gating was based on forward and side-scatter parameters, and purity of analyzed cells was assured with a neutrophil-specific marker for CD16 (antibody DJ130c; Dako, Glostrup, Denmark). Fluorescence intensity of 104 cells was analyzed. The relative mean fluorescence intensity (MFI) was calculated as the mean fluorescence of PMN treated with specific antibody divided by the mean fluorescence of the nonspecific, isotype-matched control antibody.

Laser-scanning confocal microscopy
ß1 Integrin expression in activated PMN was detected also with laser-scanning confocal microscopy. Anti-CD18-treated PMN, with or without fMLP (10-6 M), were incubated with goat anti-mouse F(ab')2 for 20 min at 37°C. PMN were then fixed in paraformaldehyde and treated identically to the protocol described above for immunofluorescent fluorescein-activated cell sorter (FACS) analysis, using anti-ß1 integrin antibody mAb13 for detection of ß1 integrin expression. PMN were viewed in a laser-scanning confocal imaging system (Insight Plus, Meridian Instruments, Okemos, MI) under normal transmitted and laser-emitted fluorescent light. Correction for unspecific antibody binding and background fluorescence was made by comparing specific mAb fluorescence with that of samples treated with irrelevant antibody at the same concentration and incubation time.

PMN adhesion assay
Plastic tissue culture dishes (96-well) were coated overnight at 4°C with 10 µg/ml of fibronectin (Sigma), rat collagen (type I), recombinant human intercellular adhesion molecule-1 (ICAM-1; R&D Systems, Wiesbaden-Nordenstadt, Germany), or bovine serum albumin (BSA; Sigma); diluted in phosphate-buffered saline (PBS) collagen (type I); and purified from rat-tail tendons, according to standard procedures, a generous gift from Dr. Björn Öbrink (CMB, Karolinska Institutet, Stockholm, Sweden). The dishes were washed twice with PBS. Cross-linking of CD18 was induced by incubating IB4-treated PMN with goat anti-mouse F(ab')2 for 20 min at 4°C. PMN suspended in MEM (100 µl), was added to the wells (105 cells/well) together with anti-integrin antibodies and incubated at 37°C in humidified air for 20 min. Antibodies P1E6, L25.3, mAb13, and mAb16 were used at a final concentration of 20 µg/ml and IB4, at a final concentration of 10 µg/ml. In addition, IB4 (10 µg/ml) was added to all PMN suspensions subjected to CD18 cross-linking to prevent cell adhesion via nonbound CD18 molecules exposed on the cell surface. After the incubation period, the wells were washed twice with cold PBS to remove nonadherent cells, and PMN adhesion was quantified by assaying myeloperoxidase (MPO) activity in the remaining cell sample.

MPO assay
The PMN-specific enzyme MPO was quantified as previously described by Suzuki et al. [19 ]. In brief, PMN were lysed by addition of 100 µl 0.5% hexadecyltrimethylammonium bromide in 50 mM potassium phosphate buffer (pH 6.0) to each well. The enzyme activity in samples from each well was determined spectrophotometrically (Titertec Multiscan MCC, Flow Laboratories, McLean, VA), as the change in absorbance at 650 nm that occurs in the redox reaction of H2O2-tetramethylbenzindine catalyzed by MPO. For calculation of a standard curve, a known number of PMN in suspension were serially diluted, lysed, and analyzed for MPO activity.

PMN invasion into gels of collagen (type I)
Gels were formed in 24-well culture dishes (250 µl/well) by mixing 8.5 vol of rat collagen solution at a concentration of 1.5 mg/ml with 1 vol of x10 MEM and 0.5 vol of 4.4% NaHCO3 solution. fMLP at a final concentration of 10-7 M was added to the gel prior to polymerization. CD18 cross-linking was performed by incubating IB4-treated PMN with goat anti-mouse F(ab')2 at 4°C for 20 min. PMN (0.5x106) were suspended in 200 µl MEM containing 10-9 M fMLP, placed on top of the polymerized gels, and incubated in humidified air for 30 min at 37°C. PMN invaded the gel along the established chemotactic gradient with a directional movement toward the bottom of the well. Anti-integrin mAbs were added to the cell suspension at the same concentrations as those used in the adhesion assay described above. As indicated in the protocol above used for PMN adhesion, anti-CD18 mAb IB4 was added to all PMN suspensions subjected to CD18 cross-linking to prevent cell adhesion via nonbound CD18 molecules exposed on the cell surface. Four experiments were run in duplicate gels, and 10 randomly chosen microscopic fields (with a defined area of 0.0625 mm2) were analyzed in each gel with a Leitz Orthoplan microscope equipped with a water immersion lens (Leitz UOx55W, NA 0.80). PMN invasion into the gel was quantified by counting all cells detected within the gel when focusing down through the entire gel thickness.

Statistical analysis
Data are presented as means ± SD. Statistical significance was calculated using the Mann-Whitney test for independent samples.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
CD18 cross-linking results in rapid and sustained upregulation of ß1 integrin expression on human PMN
Isolated human blood PMN in suspension were subjected to antibody cross-linking of CD18, stimulation with fMLP, or a combination of both. The expression of the common ß1 integrin chain (CD29) in these cells, as determined by immunofluorescence flow cytometry, was compared with that in nonactivated PMN. A rapid and persistent upregulation of ß1 integrins (Fig. 1a ), which was potentiated by simultaneous stimulation with fMLP (Fig. 1b) , resulted from PMN activation through CD18 cross-linking. Limited upregulation of ß1 integrins was also seen in PMN stimulated only with fMLP (Fig. 1c) and in PMN when fMLP stimulation was combined with anti-CD18 mAb treatment (Fig. 1d) . Minimal, nonsignificant shifts in ß1 integrin expression were observed in untreated cells (Fig. 1f) . As shown in Figure 1e , herbimycin A (30 µM), when present during combined CD18 cross-linking and fMLP stimulation, almost completely inhibited ß1 integrin upregulation, indicating involvement of intracellular tyrosine kinase activity in the process studied.



View larger version (29K):
[in this window]
[in a new window]
 
Figure 1. FACS analysis of ß1 integrin expression on isolated human blood PMN. Thin line, basal integrin expression; dashed line, integrin expression after 5 min incubation; bold line, expression after 30 min incubation, according to the experimental protocol. CD18 cross-linking resulted in upregulation of ß1 integrin-surface expression (a) that was further increased by simultaneous stimulation with fMLP (10-6 M) (b). fMLP stimulation alone (c) or combined with antibody blockade of CD18 (d) caused a minor increase in ß1 integrin expression. Treatment of cells with herbimycin A (30 µM) prevented upregulation of ß1 integrins in response to combined fMLP stimulation and CD18 cross-linking (e). Limited expression of ß1 integrins was detected in untreated cells (f). Vertical line, 99th percentile of fluorescence events for cells stained with irrelevant, species-matched IgG. Histograms are representative tracings of 3–4 analyses for each antibody.

 
Comparison between the mean fluorescence values for the different treatment groups revealed a statistically significant upregulation of ß1 integrins (vs. untreated PMN) only in PMN that were subjected to CD18 cross-linking, with or without simultaneous fMLP stimulation (Fig. 2 ). Notably, combined cross-linking of CD18 and fMLP stimulation acted synergistically on ß1 integrin upregulation in PMN. Incubation with irrelevant isotype-matched control antibody and secondary F(ab')2, using the same protocol as that for the anti-CD18 mAb, was ineffective in increasing ß1 integrin expression (unpublished results). Together, these data indicate that ligation of ß2 integrins in combination with chemotactic stimulation causes upregulation of ß1 integrins in PMN via tyrosine kinase-dependent mechanisms.



View larger version (22K):
[in this window]
[in a new window]
 
Figure 2. Surface expression of ß1 integrins on isolated human PMN after 30 min incubation at 37°C. MFI is the staining intensity of PMN treated with anti-ß1 integrin antibody relative to that of PMN treated with irrelevant mouse IgG. CD18 cross-linking resulted in significant upregulation of ß1 integrin expression that was enhanced by simultaneous fMLP stimulation. Notably, upregulation of ß1 integrins was relatively insensitive to fMLP stimulation alone. Herbimycin A prevented upregulation of ß1 integrins in response to combined CD18 cross-linking and fMLP stimulation (*p<0.05 vs. untreated cells).

 
Surface expression and membrane distribution of ß1 integrins in PMN were characterized with laser-scanning confocal microscopy also (Fig. 3 ). In harmony with the FACS data presented in Figures 1 and 2 , ß1 integrin expression was sparse in PMN not subjected to receptor cross-linking (Fig. 3a 3b 3c 3d) but markedly increased after CD18 cross-linking (Fig. 3e) . However, as evident from the micrographs (Fig. 3d 3e 3f) , clustered distribution of ß1 integrins was observed not only in PMN subjected to CD18 cross-linking but also in PMN stimulated with fMLP. Interestingly, as observed in FACS analysis (Figs. 1d and 2) and confocal microscopy (Fig. 3d) , blockage of CD18 in PMN opposed the effect of fMLP stimulation on upregulation of ß1 integrins. This could be related to the fact that chemoattractants like fMLP are known to activate ß2 integrins and that some unspecific interaction mediated by these receptors during the incubation period could lead to outside in signaling and subsequent ß1 integrin expression. This should then be prevented by anti-CD18 mAb treatment.



View larger version (60K):
[in this window]
[in a new window]
 
Figure 3. Enhanced, transmitted light images of isolated human PMN (left panel), and corresponding images in laser-emitted fluorescent light showing immunofluorescent staining for ß1 integrins (mAb13 recognizing CD29) on the PMN cell surface (right panel). Low levels of ß1 integrin expression were detectable in unstimulated PMN (a). fMLP stimulation resulted in limited upregulation of receptor expression (b) that was, in part, inhibited by anti-CD18 mAb treatment (d). Antibody cross-linking of CD18 resulted in pronounced clustered expression of ß1 integrins (e), which was further increased by costimulation with fMLP (f). Original bar size = 10 µm.

 
fMLP-stimulated PMN adhesion to collagen and fibronectin is increased by CD18 cross-linking and dependent on ß1 integrin function
In a series of experiments, we investigated adhesion of fMLP-stimulated PMN to the matrix proteins fibronectin and collagen (type 1). ICAM-1 and BSA were chosen as control substrates. As previously demonstrated by numerous investigators, we found that fMLP stimulation induced significant PMN adhesion to all four substrates and that antibody blockade of CD18 resulted in markedly reduced adhesion, indicating a critical role of ß2 integrins in this process (Fig. 4 ). PMN adhesion to ICAM was almost completely blocked by anti-CD18 treatment, whereas there was still some adhesion to the other three substrates. Interestingly enough, in PMN where CD18 was cross-linked with secondary F(ab')2 fragments together with fMLP stimulation, adhesion to fibronectin and collagen was potentiated, despite the presence of anti-CD18 mAb in excess and above the level seen for cells treated with fMLP only. Adhesion to ICAM-1 and BSA, alternatively, remained at the low level seen after CD18 blockage. The most pronounced increase in adhesion following CD18 cross-linking was evident with fibronectin as substrate (from 36.7±8.4% to 59.1±10.3%, p<0.01). The adhesion of PMN to collagen was moderately increased (from 19.1±4.5% to 25.8±3.1%, p<0.05), whereas adhesion to ICAM-1 and BSA decreased from 72.3 ± 6.5% to 5.8 ± 1.8% and from 40.7 ± 6.9% to 13.9 ± 1.8% (p<0.01), respectively. It should be emphasized that PMN adhesion assays after CD18 cross-linking were run in saturating concentrations of anti-CD18 mAb to prevent any binding via ß2 integrin receptors. Still, adhesion of PMN to fibronectin and collagen was ~1.5 times that for cells treated with fMLP only. As shown in Figure 4 , adhesion to fibronectin and collagen of PMN subjected to CD18 cross-linking was inhibited to a significant extent by anti-ß1 integrin antibodies. However, PMN adhesion to ICAM-1 and BSA was not affected by antibodies against ß1 integrins. Thus, CD18 cross-linking in PMN resulted in increased, integrin-dependent adhesion to fibronectin and collagen but not to ICAM-1 and BSA. Taken together, these data suggest that cross-linking of CD18 provoked PMN adhesion to fibronectin and collagen via ß1 integrin receptors by mechanisms dependent on CD18-mediated PMN activation but independent of direct adhesive interactions of CD11/CD18 with these matrix proteins. In contrast, adhesion to ICAM-1 or a BSA-coated surface relied on ß2 integrin function and was not influenced by antibody cross-linking of CD18.



View larger version (18K):
[in this window]
[in a new window]
 
Figure 4. PMN adhesion (percentage of total PMN added to each well) to fibronectin, collagen, ICAM-1, and BSA in response to fMLP (10-6 M) stimulation alone (solid bars), in combination with anti-CD18 mAb treatment (open bars), or CD18 cross-linking (hatched bars). fMLP stimulation, together with CD18 cross-linking, was also combined with anti-ß1 integrin mAb treatment (cross-hatched bars). Anti-CD18 mAb treatment resulted in inhibition of fMLP-stimulated PMN adhesion to all four substrates. fMLP stimulation combined with CD18 cross-linking increased PMN adhesion to fibronectin and collagen but not to ICAM-1 or BSA. The PMN adhesion to fibronectin and collagen after CD18 cross-linking was markedly inhibited by anti-ß1 integrin mAb treatment. It should be noted that an excess of anti-CD18 mAb was present during the adhesion assay of anti-CD18 mAb-treated cells and those subjected to CD18 cross-linking. Data represent means ± SD of six separate experiments in each treatment group (*p<0.05).

 
PMN subjected to CD18 cross-linking adhere to fibronectin via {alpha}4 and {alpha}5 integrin and to collagen via {alpha}2 integrin
In a second set of experiments, adhesion to matrix proteins of PMN subjected to combined CD18 cross-linking and fMLP stimulation was studied with respect to involvement of specific subpopulations of ß1 integrin receptors. By mAb blockade of the {alpha}4 integrin subunit (Fig. 5a ), adhesion to fibronectin of PMN subjected to CD18 cross-linking and fMLP stimulation was reduced to 74 ± 8% of control. A more pronounced inhibition of PMN adhesion was seen after blockage of the {alpha}5 subunit (55±6% of control). Blockade of the {alpha}4 and {alpha}5 subunits resulted in reduced adhesion closely similar to that seen after blockage of the common ß1 chain (42±12% and 45±13% of control, respectively), whereas blockade of the {alpha}2 subunit proved ineffective in modulating PMN adhesion to fibronectin. Conversely, PMN adhesion to collagen appeared to be mediated predominantly via the {alpha}2ß1 integrin (Fig. 5b) . Similarly, inhibition of ß1 or {alpha}2 was effective in blocking adhesion (36±10% and 42±11% of control, respectively), and no additional inhibition occurred after combined treatment (40±10% of control). These data suggest that PMN adhesion to fibronectin and collagen subsequent to CD18 cross-linking is mediated to a major extent via specific ß1 integrins. Apparently, ß1 integrin-dependent adhesion to fibronectin predominantly involves {alpha}5ß1 and to a lesser extent, {alpha}4ß1, whereas adhesion to collagen is mediated via {alpha}2ß1. As evident from Figure 5a and 5b , significant adhesion of PMN to fibronectin and collagen remained after function inhibition of ß1 integrin receptors. Because the experiments were performed in the presence of a saturating concentration of antibodies against CD18, the remaining adhesion has to be interpreted not to be dependent on ß1 or ß2 integrin receptors, suggesting PMN adhesion being mediated by pathways other than those studied here. Notably, ß1 integrin receptors were not involved in PMN adhesion to BSA (Fig. 5c) .



View larger version (17K):
[in this window]
[in a new window]
 
Figure 5. Effect of antibodies against the common ß chain of ß1 integrins (mAb13) and integrin subunits {alpha}2 (P1E6), {alpha}4 (L25.3), and {alpha}5 (mAb16) on PMN adhesion to fibronectin (a), collagen (b), and BSA (c) in response to CD18 cross-linking combined with fMLP stimulation. Note that mAb blockade of the common ß1 integrin chain was similarly effective in inhibiting PMN adhesion to fibronectin and collagen but without effect on cell adhesion to BSA. Data are expressed as percentage of fMLP-stimulated PMN adhesion in the absence of mAb treatment and represent means ± SD of four to six separate experiments for each treatment (*p<0.05 vs. no mAb treatment).

 
PMN chemotaxis in collagen gels is dependent on CD18-mediated activation of ß1 integrins
Chemotaxis of PMN into gels of native collagen (type 1) fibers was analyzed to disclose the potential of CD18 cross-linking to modulate PMN interaction with matrix proteins (Fig. 6 ). A significant number of PMN migrated down into the gels in response to a chemotactic gradient of fMLP. In harmony with our observations on PMN adhesion to matrix proteins, mAb inhibition of CD18 markedly reduced PMN migration, indicating a general role of ß2 integrin receptors in PMN motile responses. PMN subjected to CD18 cross-linking invaded the gel in numbers comparable with that seen for cells not exposed to anti-CD18 antibodies. The enhanced response noted in the adhesion experiments was, however, missing. The experiments using PMN subjected to CD18 cross-linking were performed in excess of anti-CD18 antibodies blocking the function of CD18 on the PMN surface. Thus, the effects seen after CD18 cross-linking were dependent on CD18-mediated PMN activation but independent of direct physical binding of the receptors to the matrix. In PMN subjected to CD18 cross-linking and PMN not treated with anti-CD18 mAb, blockade of the {alpha}2 integrin subunit or the common ß1 integrin chain resulted in largely reduced migration, whereas blockade of the {alpha}4 and {alpha}5 subunits was without effect on the parameters studied. These data show that ligation of CD18, physiologically induced by PMN adhesion to the collagen gel or artificially induced by antibody cross-linking, is a prerequisite for the {alpha}2ß1 integrin-dependent PMN migration into the gel. Supposedly, engagement of CD18 triggers upregulation of ß1 integrin expression, as demonstrated above, which then becomes indispensable for PMN migration within the gel.



View larger version (17K):
[in this window]
[in a new window]
 
Figure 6. PMN invasion into collagen gels in response to a chemotactic gradient of fMLP (solid bar) was inhibited by treatment with anti-CD18 mAb IB4 (open bar) and restored after CD18 cross-linking (hatched bar). Gel invasion of PMN stimulated with fMLP or fMLP combined with CD18 cross-linking was inhibited by an antibody against the {alpha}2 integrin subunit (P1E6) or the common ß1 chain (mAb13), whereas mAb blockade of {alpha}4 (L25.3) and {alpha}5 (mAb16) integrin subunits was without modulatory effect (*p<0.05 vs. no mAb treatment). Data represent means ± SD of four separate experiments for each treatment.

 

    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
It is well established that ß2 integrins play a key role in PMN activation and that many activation-induced PMN responses, including oxidative burst, cytotoxic activity, and phagocytosis, depend on ß2 integrin function [20 21 22 ]. In this study, we investigated the relationship between ß2 integrin engagement and the expression/function of ß1 integrin receptors previously shown to be induced in conjunction with PMN extravasation [3 , 6 , 14 ]. Ligation of ß2 integrins in PMN was achieved by antibody cross-linking of the common ß2 chain (CD18), mimicking adhesion-dependent receptor engagement [22 23 24 ]. Our data demonstrate a rapid and sustained upregulation of ß1 integrins in isolated human blood PMN upon CD18 cross-linking. Moreover, ß1 integrin expression is further increased by costimulation with fMLP, possibly because of a chemoattractant-dependent increase in ß2 integrin expression on the cell surface and, hence, more CD18 molecules available for antibody cross-linking. Limited increase in ß1 integrin expression was seen after fMLP stimulation alone; however, combined stimulation with fMLP and CD18 cross-linking was required to provoke significant ß1 integrin upregulation in PMN (3–4 times that of ß1 integrin expression in untreated cells). The level of ß1 integrin expression in these cells was comparable with that previously shown in emigrated human PMN in vivo [15 ].

The upregulation of ß1 integrins in PMN subjected to combined fMLP stimulation and CD18 cross-linking was blocked by exposure of PMN to herbimycin A, indicating involvement of tyrosine phosphorylation in this process. ß2 Integrin ligation and fMLP stimulation have been described to activate tyrosine kinases in PMN [24 , 25 ], and integrin upregulation has been shown to correlate with tyrosine kinase activity [26 ]. In contrast, activation of PMN with phorbol ester, which is known to bypass protein phosphorylation, results in limited, if any, upregulation of ß1 integrins [10 ]. Collectively, these findings suggest that tyrosine phosphorylation is a necessary yet not sufficient step for ß1 integrin upregulation in PMN. Recently, elevated intracellular Ca++ levels and activation of protein kinase C were shown to act synergistically in the activation of ß1 integrins in granulocytic HL 60 cells [27 ]. Also, CD18 cross-linking has been shown to induce Ca++-dependent responses in PMN that are not altered by herbimycin A [23 ].

The functional state of ß1 and ß2 integrins in PMN subjected to CD18 cross-linking was investigated in PMN adhesion and migration assays. Previous studies have clearly shown a fundamental role of ß2 integrins in PMN adhesion to various substrates and PMN migration under different conditions [16 , 28 29 30 ]. Consistent with these studies, we observed that fMLP-stimulated PMN adhesion to collagen, fibronectin, ICAM-1, and BSA to a major extent was ß2 integrin-dependent inasmuch as adhesion was abrogated with antibodies against CD18. We also found that PMN adhesion to collagen and fibronectin, but not to ICAM-1 and BSA, was enhanced by antibody cross-linking of CD18. Because in this situation PMN adhesion via CD18 was prevented, and what is more, the experiments were performed in excess of anti-CD18 antibodies, we conclude that PMN adhesion to fibronectin and collagen after CD18 cross-linking was mediated via mechanisms distinct from the ß2 integrins. These adhesion pathways were specific for the matrix proteins because adhesion to ICAM-1 and BSA after CD18 cross-linking did not differ from that of CD18 mAb treatment. A similar pattern to PMN/matrix adhesion was observed with regard to PMN migration in collagen gels. Thus, PMN adhesion to fibronectin, collagen, and migration in collagen after CD18 cross-linking was dependent on ligation of the ß2 integrins but independent of their physical binding capacity. As shown here, one major adhesive mechanism induced by ß2 integrin ligation was via upregulation of functional ß1 integrins. Function-blocking antibodies against ß1 integrins reduced adhesion to collagen and fibronectin of PMN subjected to CD18 cross-linking by ~50%. ß1 Integrin-dependent adhesion to fibronectin was mediated predominantly by {alpha}5ß1 and to a lesser extent by {alpha}4ß1. PMN adhesion to fibronectin has been shown previously to occur via the {alpha}4ß1 and {alpha}5ß1 integrins [3 , 12 , 31 ]. ß1 Integrin-dependent PMN adhesion to collagen, alternatively, was found to be entirely dependent on the {alpha}2ß1 integrin, which, to our knowledge, is the first demonstration of {alpha}2ß1 integrin-mediated adhesion of PMN to collagen.

As previously observed in several studies and also shown here, PMN adhere more readily to fibronectin than to collagen. We have previously shown that PMN migration in an extracellular matrix (ECM) environment can be inhibited through function blockade of the {alpha}2ß1 integrin but not the {alpha}4ß1 and {alpha}5ß1 integrins [15 ]. Combined, these findings indicate that ß1 integrins can mediate adhesive and motile cell-matrix interactions. Differences in conformational regulation of ß1 integrin receptors evoked by ligand binding [32 ] may explain differences in adhesive and dynamic functions among these receptors.

In accordance with previous studies using similar migration models, we show that blockage of ß2 integrin function resulted in an almost complete inhibition of PMN migration into collagen gels, apparently as a consequence of the inability of the cells to adhere to the gel. However, after antibody cross-linking of CD18, PMN migrated into the gel in numbers comparable with what was seen for cells not treated with antibodies, indicating that ß2 integrin ligation is a prerequisite for PMN invasion into the gel. Again, in this situation, the ability of CD18 to directly interact with the matrix proteins was impeded because of anti-CD18 mAb treatment. Our finding that PMN migration into gels after CD18 cross-linking was comparable to that for untreated PMN and was similarly dependent on the {alpha}2ß1 integrin suggests that ß2 integrins play a critical role in PMN motility by regulating the expression and function of other integrin receptors (e.g., ß1 integrins as shown here) rather than by mediating a direct physical binding to the substrate. These findings are supported by observations of crosstalk between ß1 and ß2 integrins in human T cells [33 ] and similar studies suggesting that integrin-receptor functions are significantly modulated by mechanisms related to cell-surface receptor crosstalk [34 ]. Summarizing available data on ß1 integrins in PMN, it becomes clear that the expression and function of these receptors are transient and may undergo rapid modulation during the process of extravasation and migration in extravascular tissue. We have shown that ß2 integrins, recognized as the most abundant integrin receptors in PMN and involved in various steps of PMN activation, also initiate intracellular signaling events, which fundamentally alter the state of expression and function of ß1 integrins in PMN. Thus, our findings suggest a mechanism of integrin receptor crosstalk in PMN where ligation and engagement of ß2 integrins, through binding to counterreceptors on endothelium and ECM, trigger upregulation of ß1 integrins, which then may act in concert with the ß2 integrins to optimize PMN motility in extravascular tissue.


    ACKNOWLEDGEMENTS
 
This study was supported by the Swedish Medical Reserach Council (14X-4342, 04P-10738), the Swedish Foundation for Health Care Science and Allergy Research (A98110), the Swedish National Board for Laboratory Animals, IngaBritt and Arne Lundbergs Foundation, and Karolinska Institutet.

Received December 3, 1999; revised March 20, 2000; accepted April 14, 2000.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Springer, T. A. (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm Cell 76,301-314[Medline]
  2. Carlos, T. M., Harlan, J. M. (1994) Leukocyte-endothelial adhesion molecules Blood 84,2068-2101[Abstract/Free Full Text]
  3. Kubes, P., Niu, X. F., Smith, C. W., Kehrli, M. E., Jr, Reinhardt, P. H., Woodman, R. C. (1995) A novel beta 1-dependent adhesion pathway on neutrophils: a mechanism invoked by dihydrocytochalasin B or endothelial transmigration FASEB J 9,1103-1111[Abstract]
  4. Bohnsack, J. F. (1992) CD11/CD18-independent neutrophil adherence to laminin is mediated by the integrin VLA-6 Blood 79,1545-1552[Abstract/Free Full Text]
  5. Lawson, M. A., Maxfield, F. R. (1995) Ca(2+)- and calcineurin-dependent recycling of an integrin to the front of migrating neutrophils Nature 377,75-79[Medline]
  6. Werr, J., Xie, X., Hedqvist, P., Ruoslahti, E., Lindbom, L. (1998) beta 1 integrins are critically involved in neutrophil locomotion in extravascular tissue In vivo J. Exp. Med. 187,2091-2096[Abstract/Free Full Text]
  7. Hemler, M. E. (1990) VLA proteins in the integrin family: structures, functions, and their role on leukocytes Annu. Rev. Immunol. 8,365-400[Medline]
  8. Brakebusch, C., Hirsch, E., Potocnik, A., Fassler, R. (1997) Genetic analysis of beta1 integrin function: confirmed, new and revised roles for a crucial family of cell adhesion molecules J. Cell Sci. 110,2895-2904[Abstract]
  9. Bochner, B. S., Luscinskas, F. W., Gimbrone, M. A., Jr, Newman, W., Sterbinsky, S. A., Derse-Anthony, C. P., Klunk, D., Schleimer, R. P. (1991) Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules J. Exp. Med. 173,1553-1557[Abstract/Free Full Text]
  10. Rieu, P., Lesavre, P., Halbwachs-Mecarelli, L. (1993) Evidence for integrins other than beta 2 on polymorphonuclear neutrophils: expression of alpha 6 beta 1 heterodimer J. Leukoc. Biol. 53,576-582[Abstract]
  11. Issekutz, T. B., Miyasaka, M., Issekutz, A. C. (1996) Rat neutrophils express very late antigen 4 and it mediates migration to arthritic joint and dermal inflammation J. Exp. Med. 183,2175-2184[Abstract/Free Full Text]
  12. Frieser, M., Hallmann, R., Johansson, S., Vestweber, D., Goodman, S. L., Sorokin, L. (1996) Mouse polymorphonuclear granulocyte binding to extracellular matrix molecules involves beta 1 integrins Eur. J. Immunol. 26,3127-3136[Medline]
  13. Reinhardt, P. H., Ward, C. A., Giles, W. R., Kubes, P. (1997) Emigrated rat neutrophils adhere to cardiac myocytes via alpha 4 integrin Circ. Res. 81,196-201[Abstract/Free Full Text]
  14. Roussel, E., Gingras, M. C. (1997) Transendothelial migration induces rapid expression on neutrophils of granule-release VLA6 used for tissue infiltration J. Leukoc. Biol. 62,356-362[Abstract]
  15. Werr, J., Johansson, J., Eriksson, E. E., Hedqvist, P., Ruoslahti, E., Lindbom, L. (2000) Integrin {alpha}2ß1 (VLA-2) is a principal receptor used by neutrophils for locomotion in extravascular tissue Blood 95,1804-1809[Abstract/Free Full Text]
  16. Williams, M. A., Solomkin, S. (1999) Integrin-mediated signaling in human neutrophil functioning J. Leukoc. Biol. 65,725-736[Abstract]
  17. Blanks, J. E., Moll, T., Eytner, R., Vestweber, D. (1998) Stimulation of P-selectin glycoprotein ligand-1 on mouse neutrophils activates beta 2-integrin mediated cell attachment to ICAM-1 Eur. J. Immunol. 28,433-443[Medline]
  18. Varon, D., Jackson, D. E., Shenkman, B., Dardik, R., Tamarin, I., Savon, N., Newman, P. J. (1998) Platelet/endothelial cell adhesion molecule-1 serves as a costimulatory agonist receptor that modulates integrin-dependent adhesion and aggregation of human platelets Blood 91,500-507[Abstract/Free Full Text]
  19. Suzuki, K., Ota, H., Sasagawa, S., Sakatani, T., Fujikura, T. (1983) Assay method for myeloperoxidase in human polymorphonuclear leukocytes Anal. Biochem. 132,345-352[Medline]
  20. Arnaout, M. A. (1990) Structure and function of the leukocyte adhesion molecules CD11/CD18 Blood 75,1037-1050[Free Full Text]
  21. Mazzone, A., Ricevuti, G. (1995) Leukocyte CD11/CD18 integrins: biological and clinical relevance Haematologica 80,161-175[Abstract/Free Full Text]
  22. Liles, W. C., Ledbetter, J. A., Waltersdorph, A. W., Klebanoff, S. J. (1995) Cross-linking of CD18 primes human neutrophils for activation of the respiratory burst in response to specific stimuli: implications for adhesion-dependent physiological responses in neutrophils J. Leukoc. Biol. 58,690-697[Abstract]
  23. Walzog, B., Seifert, R., Zakrzewicz, A., Gaehtgens, P., Ley, K. (1994) Cross-linking of CD18 in human neutrophils induces an increase of intracellular free Ca2+, exocytosis of azurophilic granules, quantitative up-regulation of CD18, shedding of L-selectin, and actin polymerization J. Leukoc. Biol. 56,625-635[Abstract]
  24. Walzog, B., Offermanns, S., Zakrzewicz, A., Gaehtgens, P., Ley, K. (1996) Beta2 integrins mediate protein tyrosine phosphorylation in human neutrophils J. Leukoc. Biol. 59,747-753[Abstract]
  25. Rollet, E., Caon, A. C., Roberge, C. J., Liao, N. W., Malawista, S. E., McColl, S. R., Naccache, P. H. (1994) Tyrosine phosphorylation in activated human neutrophils. Comparison of the effects of different classes of agonists and identification of the signaling pathways involved J. Immunol. 153,353-363[Abstract]
  26. Naccache, P. H., Jean, N., Liao, N. W., Bator, J. M., McColl, S. R., Kubes, P. (1994) Regulation of stimulated integrin surface expression in human neutrophils by tyrosine phosphorylation Blood 84,616-624[Abstract/Free Full Text]
  27. Rowin, M. E., Whatley, R. E., Yednock, T., Bohnsack, J. F. (1989) Intracellular calcium requirements for beta1 integrin activation J. Cell. Phys. 175,193-202[Medline]
  28. Shang, X. Z., Issekutz, A. C. (1997) Beta 2 (CD18) and beta 1 (CD29) integrin mechanisms in migration of human polymorphonuclear leukocytes and monocytes through lung fibroblast barriers: shared and distinct mechanisms Immunology 92,527-535[Medline]
  29. Gao, J. X., Issekutz, A. C. (1996) Mac-1 (CD11/CD18) is the predominant beta 2 (CD18) integrin mediating human neutrophil migration through synovial and dermal fibroblast barriers Immunology 88,463-470[Medline]
  30. Saltzman, W. M., Livingston, T. L., Parkhust, M. R. (1999) Antibodies to CD18 influence neutrophil migration through extracellular matrix J. Leukoc. Biol. 65,356-363[Abstract]
  31. Bohnsack, J. F., Zhou, X. N. (1992) Divalent cation substitution reveals CD18- and very late antigen-dependent pathways that mediate human neutrophil adherence to fibronectin J. Immunol. 149,1340-1347[Abstract]
  32. Bazzoni, G., Ma, L., Blue, M. L., Hemler, M. E. (1998) Divalent cations and ligands induce conformational changes that are highly divergent among beta1 integrins J. Biol. Chem. 273,6670-6678[Abstract/Free Full Text]
  33. Porter, J. C., Hogg, N. (1997) Integrin cross talk: activation of lymphocyte function-associated antigen-1 on human T cells alters alpha4beta1- and alpha5beta1-mediated function J. Cell Biol. 138,1437-1447[Abstract/Free Full Text]
  34. Porter, J. C., Hogg, N. (1998) Integrins take partners: cross-talk between integrins and other membrane receptors Trends Cell Biol 8,390-396[Medline]



This article has been cited by other articles:


Home page
J. Immunol.Home page
B. Petri, M. Phillipson, and P. Kubes
The Physiology of Leukocyte Recruitment: An In Vivo Perspective
J. Immunol., May 15, 2008; 180(10): 6439 - 6446.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. M. Lavigne, X. M. O'Brien, M. Kim, J. W. Janowski, J. E. Albina, and J. S. Reichner
Integrin Engagement Mediates the Human Polymorphonuclear Leukocyte Response to a Fungal Pathogen-Associated Molecular Pattern
J. Immunol., June 1, 2007; 178(11): 7276 - 7282.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. E. Green, U. Y. Schaff, M. R. Sarantos, A. F. H. Lum, D. E. Staunton, and S. I. Simon
Dynamic shifts in LFA-1 affinity regulate neutrophil rolling, arrest, and transmigration on inflamed endothelium
Blood, March 1, 2006; 107(5): 2101 - 2111.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. Ortiz-Stern and C. Rosales
Fc{gamma}RIIIB stimulation promotes {beta}1 integrin activation in human neutrophils
J. Leukoc. Biol., May 1, 2005; 77(5): 787 - 799.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
A. R. Burns, C. W. Smith, and D. C. Walker
Unique Structural Features That Influence Neutrophil Emigration Into the Lung
Physiol Rev, April 1, 2003; 83(2): 309 - 336.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
J. Dangerfield, K. Y. Larbi, M.-T. Huang, A. Dewar, and S. Nourshargh
PECAM-1 (CD31) Homophilic Interaction Up-Regulates {alpha}6{beta}1 on Transmigrated Neutrophils In Vivo and Plays a Functional Role in the Ability of {alpha}6 Integrins to Mediate Leukocyte Migration through the Perivascular Basement Membrane
J. Exp. Med., November 4, 2002; 196(9): 1201 - 1212.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
J. D. Borgquist, M. T. Quinn, and S. D. Swain
Adhesion to extracellular matrix proteins modulates bovine neutrophil responses to inflammatory mediators
J. Leukoc. Biol., May 1, 2002; 71(5): 764 - 774.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
A. K. McNally and J. M. Anderson
{beta}1 and {beta}2 Integrins Mediate Adhesion during Macrophage Fusion and Multinucleated Foreign Body Giant Cell Formation
Am. J. Pathol., February 1, 2002; 160(2): 621 - 630.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
Y.-C. Shen, C.-J. Chou, W.-F. Chiou, and C.-F. Chen
Anti-Inflammatory Effects of the Partially Purified Extract of Radix Stephaniae tetrandrae: Comparative Studies of Its Active Principles Tetrandrine and Fangchinoline on Human Polymorphonuclear Leukocyte Functions
Mol. Pharmacol., November 1, 2001; 60(5): 1083 - 1090.
[Abstract] [Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Werr, J.
Right arrow Articles by Lindbom, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Werr, J.
Right arrow Articles by Lindbom, L.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS